Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

participating in the study developed malignancies: one patient taking golimumab 100 mg plus methotrexate developed breast cancer, one patient taking placebo plus methotrexate developed Bowen's disease and squamous cell skin cancer, one patient taking golimumab 100 mg plus placebo developed basal cell cancer, and one patient taking golimumab 100 mg plus placebo developed squamous cell carcinoma. One patient receiving golimumab 100 mg plus placebo died from diarrhea, colitis and sepsis.

Anti-TNF therapies have been associated with serious and sometimes fatal risks including the risk of tuberculosis and other serious infections, malignancies, heart failure, central nervous system disorders, reactivation of hepatitis B and other serious events.

About Rheumatoid Arthritis

RA is a chronic and debilitating disease that affects approximately 1.3 million people in the United States and more than three million people in Europe. Signs and symptoms of RA include pain, stiffness and motion restriction in multiple joints. Because RA is a progressive disease, it can cause permanent joint deformity and severe disability if not diagnosed early or if initial treatment is delayed. RA can occur at any age, but is most common in adults 30-50 years old and is two-to-three times more prevalent in women than in men. The cause of RA is unknown, although genetic factors may contribute to the disease.

About Golimumab

Golimumab, the next-generation human anti-TNF-alpha monoclonal antibody from Centocor Inc. and Schering-Plough Corporation, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of RA, including a study in a methotrexate-naive patient population, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy. Golimumab targets and neutralizes both th
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... microscopic polymer light resonators that expand in the ... Photonics Laboratory have developed new optical sensors with ... sensors are ideal for detecting trace gas concentrations ... nature, and immunity to electromagnetic interference. , Although ... the MIT team conceived an extremely sensitive, compact ...
(Date:7/10/2014)... observed the fractional quantum Hall effect in bilayer graphene ... be tuned by an electric field. , The ... confined to thin sheets are exposed to large magnetic ... thousands of individual electrons behave as a single system. ... well established, many details of this collective behavior remain ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... Ariz., April 23 ImaRx Therapeutics,Inc. (Nasdaq: ... into an agreement,with Abbott Laboratories pursuant to which ... non-recourse promissory note with Abbott issued in,connection with ... title to,the urokinase assets, including the remaining inventory ...
... (NYSE: SGP ) today announced two agreements ... in Europe. These agreements are,in connection with conditions ... its October 2007 clearance of Schering-Plough,s acquisition of ... In two separate agreements, Pfizer and Virbac, ...
... today,announced that on April 22, 2008 its management ... Emerging Business Awards, known as the "Bennies.",BioNanomatrix won ... group of growing entrepreneurial firms in the Philadelphia ... the,award on behalf of the company., The ...
Cached Biology Technology:ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe 2BioNanomatrix Named 'Best Management Team' at the 2008 Ben Franklin Emerging Business Awards 2
(Date:7/10/2014)... This news release is available in German . ... scientists, including researchers from DESY, has caught a central step ... led by Prof. Petra Fromme from Arizona State University used ... Accelerator Laboratory SLAC to record still frames of a molecular ... and oxygen, a process that maintains the oxygen in earth,s ...
(Date:7/10/2014)... While careful management has helped stabilize or even ... parts of Europe, the situation in the Mediterranean ... a new report evaluating nine fish species reported ... on July 10, scientists call for stringent ... fisheries regulations, and advanced management plans in Mediterranean ...
(Date:7/10/2014)... of overfishing in the English Channel has resulted in ... and left fishermen ,scraping the barrel, for increasing amounts ... cod, haddock and many other species at the head ... many removed from the area completely., These are some ... biologists at Plymouth University, in association with international non-profit ...
Breaking Biology News(10 mins):Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3Mediterranean fish stocks show steady decline 2Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 2Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 3
... paper being presented in two American Physiological Society ... team demonstrated "for the first time that mitochondria ... mitochondria may mechanically regulate nuclear function." , The ... years, reported that it recently "found a very ...
... There's no doubt that laughter feels good, but is ... do about it? , In a paper being presented ... 2006, Lee S. Berk of Loma Linda University, reports ... but just the anticipation of the "mirthful laughter" involved ...
... different plant species are not only more productive, they ... climate extremes, pests and disease over long periods of ... issue of Nature, are the culmination of 12 years ... Ecology at the University of Minnesota, to explore the ...
Cached Biology News:First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown 2First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown 3Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent 2Just the expectation of a mirthful laughter experience boosts endorphins 27 percent, HGH 87 percent 3Biodiversity key to sustainable biofuel according to University of Minn. researcher's findings 2
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
... Virgin, optically clear polystyrene with frosted ... coordinates for cell counting. 100% integrity ... a new product number, created to ... showing no availability yet, please order ...
... CellBIND surface is produced by a ... more hydrophilic surface giving more consistent, ... and yields. CellBIND enhances cell attachment ... reduced serum or serum-free medium. • ...
Biology Products: